Health Care • Medical/Dental Instruments
$3.97 ▲ +0.02
(+0.51%)
MKT CAP: $579.3M • VOL: 4.04M
52W L $3 52W H $8
MDXG // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $418.6M | $348.9M | $321.5M |
| YoY Revenue Growth % | +20.0% | +8.5% | — |
| Gross Profit | $345.6M | $288.8M | — |
| Gross Margin % | 82.6% | 82.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $63.9M | $58.9M | $37.1M |
| Operating Margin % | 15.3% | 16.9% | 11.5% |
| Net Income (GAAP) | $48.6M | $42.4M | $58.2M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $74.0M | $66.2M | $26.8M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $74.0M | $66.2M | $26.8M |
| FCF Margin % | 17.7% | 19.0% | 8.3% |
| Return on Invested Capital (ROIC %) | 47.2% | 43.7% | — |
| Cash & Short-Term Equivalents | $166.1M | $104.4M | — |
| Total Debt (Short + Long Term) | $16.5M | $17.8M | — |
| Total Stockholders' Equity | $256.5M | $193.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MDXG.